INS and Alzheimer disease: Given, then, that the brain is an insulin sensitive organ [14, 28, 29] with variable expression of insulin receptors in many areas, including the olfactory bulb, neocortex, hippocampus, amygdala, hypothalamus, and cerebellum [30, 31], antidiabetics capable of reducing systemic insulin resistance and hence potentially BIR have drawn increasing interest as potential AD treatments [32–36].